• MustGrow received a first development milestone payment from Bayer under a December 2023 license and collaboration agreement.
• Deal grants Bayer rights for soil applications of MustGrow’s mustard-based biocontrol technology across Europe, the Middle East, and Africa.
• Further milestone payments depend on additional development achievements; royalties and manufacturing fees would begin if commercial sales start.
• MustGrow estimates total upfront, milestones, and Bayer-funded development work could reach USD 35-40 million over 5-7 years.
• Bayer will lead regulatory filings and market development in the territory; MustGrow expects minimal incremental costs beyond supplying test product.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MustGrow Biologics Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608210700NEWSFILECNPR____20260821_310671_1) on August 21, 2026, and is solely responsible for the information contained therein.